NDAINTRAVENOUSPOWDER
Approved
Dec 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
7/8 — Comprehensive
CASPOFUNGIN ACETATE (caspofungin acetate) by Fresenius Kabi is [see microbiology ()]. Approved for fungal infection, invasive candidiasis, candidiasis. First approved in 2016.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Caspofungin acetate is an intravenous echinocandin antifungal agent approved for treating invasive fungal infections including invasive candidiasis, aspergillosis, and pneumocystis pneumonia. It functions as a fungal cell wall synthesis inhibitor targeting beta-glucan synthase. The drug is administered as an IV powder formulation in hospital and critical care settings.
$0.819MPart D
PeakStable
6.6 years to LOEProduct is in peak commercial phase with modest Medicare spending; brand team likely focused on maintaining market position against generic entry.
Mechanism of Action
[see Microbiology ()].
Indications (3)
Worked on CASPOFUNGIN ACETATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.